News

As pharmaceutical and biotech companies look to speed development, lower cost, and reduce technical risks associated with new drug development, they are increasing the number and types of collaborative relationships they are forming with other developers.

According to Tufts CSDD R&D Management Report, more than half of all new drugs approved in the United States between 2000 and 2011 were developed by companies that collaborated in one form or another with other entities.

ICR has announced two new courses for December 2014 about the impact of the European Union regulation and essential line management.

Fujitsu Limited and the Alliance for Clinical Research Excellence and Safety announced the formation of a Strategic Alliance

As the biopharmaceutical industry continues to move down an outsourcing path, it is essential that logical sourcing strategies and operational processes exists and align with corporate strategy.

Fujitsu and ACRES have linked up to address challenges facing the development of medicines and health-related research endeavors.

While at the 2014 NYBIO conference, Dr. Sam Waksal from Kadmon had the opportunity to address the audience regarding the state of the biopharmaceutical industry.

Pharmaceutical sponsors conducting clinical trials in the Asia Pacific region have a rare opportunity at hand...

Expansion of Venn's service offering into Data Management & Randomisation

IAOCR and the Association of Clinical Research Professionals have announced a new collaborative agreement

Rare disease research offers a lot for people in the world of clinical trials and drug development to think about.

IAOCR and the Association of Clinical Research Professionals (ACRP) are pleased to announce a new collaborative agreement.

Pressure to shorten study start-up timelines puts clinical supply management in the crosshairs.

Method designed to reduce the time gap between protocol approval and recruitment is examined.

New phase of innovation initiative emphasizes focus on research networks, adaptive trials, and personalized medicine, among other key areas.

eGSP-driven approach focuses on overcoming operational challenges through data integration.

Consumer groups, research organizations, and Congress are pressing for more inclusive clinical research.

IMS Health

Longer-term strategic issues are making already high-investment, high-risk decisions to place studies overseas even more complex.

Unique feedback from patient survey could help inform future clinical supply design and implementation.

Breaking through the confusion around fair market value when applying the concept to study budgets.

CRO/Sponsor: Clinical Supply Survey, Strategies Sites: Fair Market Value Debate Clinical Technology: Optimizing Supply Chain Data Trial Design: Multi-site Pre-implementation Also in this issue: European Innovation Initiative, Part II Medicine Kits: The Patient Perspective Global Trials Need Strategic Touch

Synexus has opened a research center in Bochum.

Synexus has opened its 23rd Dedicated Research Centre in Bochum

As Europe departs for its annual holiday the question remains unresolved as to what to expect from the new European Parliament in terms of the principal interest of readers of Applied Clinical Trials.

In mid-July, the SAS Press Program released a new book titled Risk-Based Monitoring and Fraud Detection in Clinical Trials Using JMP and SAS.

Hangzhou Tigermed Consulting Co., Ltd. and Frontage Laboratories, Inc. today announced completion of the previously announced investment agreement.

Hangzhou Tigermed Consulting and Frontage Laboratories announced completion of the previously announced investment agreement